An external Food and Drug Administration advisory panel recommended in July 2026 that the agency drop compounding restrictions on six out of seven evaluated peptides, including BPC-157.

From the articleTrump administration advances plan for peptide drugs favored by RFK Jr.Also in US FDA moves to ease rules on compounding some peptides | Межа, Trump administration advances plan for peptide drugs favored by RFK Jr., RFK Jr.’s Agency Sends Plan for Peptide Drugs to White House, FDA advances peptide push to White House, US FDA takes step to change peptide compounding policy | Reuters